CSRA's DynPort Vaccine Company wins $159M NIAID contract

CSRA Inc.'s subsidiary DynPort Vaccine Company LLC received a multiple-award IDIQ contract valued up to $159 million from the National Institute of Allergy and Infectious Diseases to manage medical product development initiatives.

“DVC has been successfully conducting product development for government agencies for nearly 20 years.”prnewswire.com

• 1 source
• prnewswire.comCSRA's DynPort Vaccine Company to Help Advance Medical Products for the National Institute of Allergy and Infectious DiseasesCSRA Inc.Dec 27, 2016

Summarized from public sources; check the original articles before acting on it.